A detailed history of Sheets Smith Investment Management transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Sheets Smith Investment Management holds 11,896 shares of HALO stock, worth $571,126. This represents 0.76% of its overall portfolio holdings.

Number of Shares
11,896
Previous 12,066 1.41%
Holding current value
$571,126
Previous $510,000 32.55%
% of portfolio
0.76%
Previous 0.59%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

SELL
$40.06 - $59.44 $6,810 - $10,104
-170 Reduced 1.41%
11,896 $676,000
Q2 2022

Aug 22, 2022

BUY
$37.35 - $48.3 $450,665 - $582,787
12,066 New
12,066 $510,000
Q4 2021

Mar 24, 2022

SELL
$31.82 - $40.75 $371,371 - $475,593
-11,671 Closed
0 $0
Q4 2020

Feb 24, 2021

BUY
$25.81 - $43.62 $301,228 - $509,089
11,671 New
11,671 $498,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.69B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Sheets Smith Investment Management Portfolio

Follow Sheets Smith Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sheets Smith Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Sheets Smith Investment Management with notifications on news.